Technology & Innovation

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.

SHERIDAN, WYOMING - December 19, 2025 - Merck said the EMA's CHMP has recommended approval of an expanded European indication for WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH), a move that-if confirmed by the European Commission-could broaden use to include WHO Functional Class (FC) IV patients and strengthen the product's positioning around morbidity and mortality benefit.

SHERIDAN, WYOMING - December 19, 2025 - Merck Animal Health says the U.S. Food and Drug Administration (FDA) has granted conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution), positioning the pour-on as a new systemic parasiticide option for U.S. beef operations and replacement dairy heifers facing New World screwworm (Cochliomyia hominivorax) larvae (myiasis) risk and cattle fever tick (Rhipicephalus microplus) pressure.

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

SHERIDAN, WYOMING - December 19, 2025 - As illegal and abusive drone activity increasingly threatens people and critical infrastructure-especially near air traffic assets-industry association UAV DACH is urging European and national policymakers to establish clearer rules, shared visibility, and coordinated capabilities for effective drone detection and defense across Europe.

SHERIDAN, WYOMING - December 19, 2025 - Henry Schein One says adoption of its cloud-native Dentrix Ascend platform is accelerating as dental groups and DSOs move away from legacy practice management systems to standardize operations, reduce administrative friction, and embed AI into everyday workflows.

Cloud migration becomes a scaling decision, not an IT project
Across U.S. dentistry, consolidation and multi-location growth are forcing operators to treat practice management software as core infrastructure. Henry Schein One reported that nearly 600 practices migrated from alternative systems to Ascend over the past 12 months, adding to the broader Dentrix customer base of more than 48,000 practices using Dentrix technology for clinical, operational, and financial workflows. The company also said monthly Ascend installations more than doubled year over year as practices transitioned away from legacy setups.

SHERIDAN, WYOMING - December 19, 2025 - MYTHIC, an overseas high-tech enterprise focused on anti-drone technologies, is expanding its profile as a low-altitude security provider by combining drone detection, intelligent identification, precise tracking, and efficient suppression into integrated defense systems designed for high-value, high-risk environments.

From point solutions to "intelligent airspace security barriers"
MYTHIC frames its core proposition as end-to-end protection against unauthorized UAV activity-built to perform in complex operational settings where disruption is not an option. The company says its solutions are deployed in airports, ports, petrochemical bases, hospitals, schools, luxury hotels, shopping malls, key public safety protection sites, and government office areas, reflecting buyer demand for layered protection that can be tuned to site constraints.

SHERIDAN, WYOMING - December 18, 2025 - Motor Presse Stuttgart is kicking off a year-long anniversary cycle for its flagship automotive media brand auto motor und sport, marking 80 years of publishing with a premium-format XXL issue and a 2026 editorial program designed to deepen reach across print and digital channels.

An anniversary issue designed as a premium brand statement
Motor Presse Stuttgart is launching the jubilee year with an oversized special edition of auto motor und sport featuring a refined additional cover, larger format, and an expanded 232-page scope. The move signals a deliberate positioning strategy: in a fragmented media environment, special-interest publishers are increasingly using premium "event issues" to reinforce brand authority, extend dwell time, and create high-impact inventory for partners.

SHERIDAN, WYOMING - December 18, 2025 - Citroën is using the 2026 Brussels Motor Show as a strategic showcase for its renewed electric portfolio and brand positioning, placing compact EV innovation, comfort-led SUVs and electric motorsport on the radar of European dealers, fleet buyers and mobility partners.

Brussels stand becomes a live lab for Citroën's electrification strategy

At the show, which opens to the public on 9 January 2026, Citroën is building a stand that mirrors its current transformation: colourful, modern and highly focused on accessible, electrified mobility. Alongside the world premiere of the ELO concept, visitors will see the new C5 Aircross as the brand's flagship SUV, the Ami in its new Dark Side edition, and a Formula E single-seater that signals Citroën's next era in electric motorsport.

For B2B stakeholders, the line-up illustrates how Citroën is repositioning its range around:

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.